Abstract
Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
Original language | English (US) |
---|---|
Pages (from-to) | 313-318 |
Number of pages | 6 |
Journal | Seminars in Thrombosis and Hemostasis |
Volume | 40 |
Issue number | 3 |
DOIs | |
State | Published - 2014 |
Keywords
- anticoagulation
- bleeding
- cancer
- chemotherapy
- survival
- venous thromboembolism
ASJC Scopus subject areas
- Hematology
- Cardiology and Cardiovascular Medicine
- Medicine(all)